Skip to main content

Scleroderma/Raynauds

IL-6 Inhibition in Refractory Systemic Sclerosis

Sep 22, 2021

A small, single-center cohort analysis of difficult, refractory systemic sclerosis (SSc) patients showed that treatment with tocilizumab (TCZ), an interleukin-6 inhibitor, resulted in significant improvement in joint and skin involvement, regardless of SSc disease duration or subtype. 

Read Article

RheumNow Podcast – Do More DMARDs Mean More Switching? (9.17.2021)

Sep 16, 2021

Smartphones and diet; COVID-19 and the numbers - reassuring or not, and what about masks?; and do more drugs mean more switching, less persistence, and patient adherence goes up...or down? All this and more news and journal reports in this week's episode.

Read Article
ICYMI: https://t.co/wM1iRxtHvk The interleukin-6 inhibitor, tocilizumab (TCZ), was studied in a cohort of difficult systemic sclerosis (SSc) and was shown to be effective in refractory joint and skin disease with good long-term retention rates and disease stabilization. https://t.co/A8dfCksp3b
Dr. John Cush @RheumNow( View Tweet )
Sep 12, 2021
A retrospective study of systemic sclerosis patients shows that acute hospitalization and mortality were not uncommon and were often linked to SSc-related lung disease. #RheumNow https://t.co/s5wSlndTrt https://t.co/KHz9LYZVAK
Dr. John Cush @RheumNow( View Tweet )
Sep 10, 2021

Risk Factors Associated with Systemic Sclerosis Hospitalization

Sep 09, 2021

A retrospective study of systemic sclerosis patients shows that acute hospitalization and mortality were not uncommon and were often linked to SSc-related lung disease.



Record review of 95 SSc patients from a single-centre cohort seen between 2010 and 2020 found that over half (53

Read Article
Cardiac coronary Ca score (CCS) in 20 asymptomatic systemic sclerosis (SSc) pts vs controls.CCS incr (& higher scores) in 45% SSc vs 10% controls. CCS values higher in Limited vs diffuse SSc. CCS > 100 assoc w/ age, dz duration obesity https://t.co/aDWpoePqXK

Dr. John Cush @RheumNow( View Tweet )

Sep 09, 2021
https://t.co/wM1iRxtHvk The interleukin-6 inhibitor, tocilizumab (TCZ), was studied in a cohort of difficult systemic sclerosis (SSc) and was shown to be effective in refractory joint and skin disease with good long-term retention rates and disease stabilization. https://t.co/UBjpHUlb1l
Dr. John Cush @RheumNow( View Tweet )
Sep 06, 2021
NIAID will study COVID‐19 Booster Vaccine in Autoimmune Disease Non‐Responders (including MS, RA, SLE, Scleroderma,pemphigus); 20 sites, 600 pts (taking MTX, MMF or RTX) w/ poor resp to mRNA vax & recv 3rd booster vax. https://t.co/YwCvGnX21F https://t.co/th2WoRv1ng

Dr. John Cush @RheumNow( View Tweet )

Aug 31, 2021
https://t.co/wM1iRxtHvk The interleukin-6 inhibitor, tocilizumab (TCZ), was studied in a cohort of difficult systemic sclerosis (SSc) and was shown to be effective in refractory joint and skin disease with good long-term retention rates and disease stabilization. https://t.co/XkJDVwJLwb
Dr. John Cush @RheumNow( View Tweet )
Aug 22, 2021

RheumNow Podcast – Driving in Pain (8.20.2021)

Aug 20, 2021

You know, I'm a very good driver. We all think we're great drivers - but consider what it's like to drive in pain: would you be a good driver? Also, I want you to consider the diagnosis of calcium pyrophosphate dihydrate disease (CPPD). But first, let's look at a study out of Scotland, looking

Read Article

Tocilizumab in Refractory Skin and Joint Scleroderma

Aug 18, 2021

The interleukin-6 inhibitor, tocilizumab (TCZ), was studied in a cohort of difficult systemic sclerosis (SSc)  and was shown to be effective in refractory joint and skin disease with good long-term retention rates and disease stabilization.



TCZ is currently FDA approved for use in SSc

Read Article
Biomarkers predict early ILD in systemic sclerosis: https://t.co/9z4Swjjy4p we need a biomarker for early disease!

Peter Nash @drpnash( View Tweet )

Aug 13, 2021
Nice rvw of tx for SSc-ILD by @sclerodermaUM et al Endorse: "MMF is now considered the standard of care as first line therapy for the treatment of SSc-ILD" Reasonable chart, but wish we could offer more HSCT Also, I'm seeing a LOT of INappropriate early use of nintedanib https://t.co/n1R73EbrXZ
Mike Putman @EBRheum( View Tweet )
Aug 10, 2021
What predicts ILD progression in Systemic Sclerosis? Study of 138 SSc pts; 72% had ILD, 35% FVC decline (F/U 2.9y). Only Scl-70 A positivity predicted FVC decline at 5yrs. HRCT Esophageal dilation had nonsignificant DLCO decline, but not FVC https://t.co/fE0JCsZ44O

Dr. John Cush @RheumNow( View Tweet )

Jul 29, 2021
NEJM Image: Salt-and-Pepper Skin Changes in Systemic Sclerosis. 68yoM with skin changes of chest and back and with shortness of breath. Exam:showed “salt-and-pepper” skin changes, w/ CT evidence of lung fibrosis. https://t.co/Pz7mKUD2Yx

Dr. John Cush @RheumNow( View Tweet )

Jul 22, 2021

ACR/Vasculitis Foundation 2021 Guidelines for ANCA–Associated Vasculitis

Jul 14, 2021

Chung et al have published the 2021 treatment guielines for the management of antineutrophil cytoplasmic antibody–associated vasculitis, including granulomatosis with polyangiitis, microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis. These guidelines are put forth by the

Read Article
Hands-Down Rheumatology - Sarcoidosis usually presents as a monarthritis or oligoarthritis. Late sarcoid arthritis affects knees, ankles, fingers (dactylitis). Bony lesions show honeycomb trabecular pattern). https://t.co/lmXBbJz6ts https://t.co/oDYrBiPuIX
Dr. John Cush @RheumNow( View Tweet )
Jul 09, 2021

ICYMI: 2020 Rheumatology Year in Review

Jul 08, 2021

2020 was historic, memorable and game-changing. Under the cloud of COVID-19, there were many significant and memorable advances and setbacks for the rheumatology world. In our accounting of most read articles for 2020, (not surprisingly) 17/20 were COVID-related. Below, are our top news items

Read Article

ICYMI: Actemra FDA Approved for Systemic Sclerosis Interstitial Lung Disease

Jul 06, 2021

Genentech announced Thursday that the US Food and Drug Administration approved tocilizumab (Actemra) for the treatment of Systemic Sclerosis-associated Interstitial Lung Disease (SSc-ILD), specifically indicated for slowing the rate of decline in pulmonary function in adults SSc-ILD.

Read Article

RheumNow Podcast – As Good As I Ever Was (7.2.2021)

Jul 02, 2021

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.

Read Article
Retrospective study of 258 IBD patients, 17% had MRI sacroiliitis (73% w/ bone marrow edema. Sacroiliitis was significantly associated w/ Female gender, back pain, and later age of CD diagnosis. >two-thirds of these pts never seen a rheumatologist. https://t.co/HYhAU6aRIf

Dr. John Cush @RheumNow( View Tweet )

Jun 29, 2021

The Potential of Rituximab Efficacy in Systemic Sclerosis

Jun 28, 2021

Rituximab (RTX) has been in the news a lot lately; more surprisingly for its potential benefits in progressive systemic sclerosis (SSc).

Ebata and colleagues have published the results of a double-blind, randomised, placebo-controlled trial comparing intravenous RTX to placebo in 56 SSc

Read Article
What Does Limited Scleroderma with ScL70 Look Like? https://t.co/nlsSiO83Bz https://t.co/idPlQSPhRn
Dr. John Cush @RheumNow( View Tweet )
Jun 22, 2021
Machine learning to model risk for SSc-ILD ⭐️predict time to lung function decline ⭐️needs larger sample size Abs#OP0150 #EULAR2021 @RheumNow

Robert B Chao, MD @doctorRBC( View Tweet )

Jun 03, 2021
Positive RCT of Rituximab in Systemic sclerosis https://t.co/WsDZeollu0

Richard Conway @RichardPAConway( View Tweet )

Jun 02, 2021
×